Aldeyra Therapeutics
Tracked across 3 events · 35 articles · First seen Apr 03, 2025 · Last active May 28, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Regulatory
Impact: Aldeyra Therapeutics is being investigated for potential securities law violations after its lead drug candidate, reproxalap, failed to meet FDA requirements, causing its stock price to fall significantly.
Apr 03, 2025 · 6 articles
Regulatory
Rosen Law Firm has filed a securities class action lawsuit against Aldeyra Therapeutics, alleging that the company made false and misleading statements regarding the inconsistent results of its reproxalap clinical trials. The lawsuit covers the…
Impact: Aldeyra Therapeutics is the defendant in a securities class action lawsuit, accused of making false and misleading statements regarding its reproxalap clinical trials, which could lead to significant financial damages.
May 03, 2026 · 8 articles
Business
A class action lawsuit has been filed against Aldeyra Therapeutics by Bronstein, Gewirtz & Grossman, LLC, on behalf of investors who purchased Aldeyra Therapeutics securities between November 3, 2023, and March 16, 2026. The lawsuit…
Impact: Aldeyra Therapeutics is the defendant in a class action lawsuit alleging that it made false and misleading statements regarding the clinical trials of its drug candidate, reproxalap, which could lead to significant financial and reputational damage.
Apr 24, 2026 · 21 articles
100
Bronstein, Gewirtz & Grossman, LLC filed class action lawsuit Aldeyra TherapeuticsAldeyra Therapeutics Class...
100
Rosen Law Firm filed lawsuit Aldeyra TherapeuticsAldeyra Therapeutics...
NEWSDESK
Track Aldeyra Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard